BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines BRUKINSA — United States Net Product Revenue by Year
BRUKINSA — United States Net Product Revenue ($M) ($M)
BeOne Medicines BRUKINSA — United States Net Product Revenue: $946M in FY2023, up 142.6% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“U.S. sales of BRUKINSA totaled $945.6 million for the year ended December 31, 2023 compared to $389.7 million in the prior year, representing growth of 142.6%.”
Source: Form 10-K (filed 2024-02-26) ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — United States Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 946 | +142.6% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 390 | +236.8% | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 116 | +535.7% | Form 10-K (filed 2022-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 18.2 | – | Form 10-K (filed 2022-02-28) ↗ |
Breakdown
What makes up BRUKINSA — United States Net Product Revenue
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — United States Net Product Revenue ($M), annual FY2020–FY2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-brukinsa-us
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.